吉非替尼治疗不可治愈性皮肤鳞状细胞癌的单臂II期临床试验
这项单臂II期研究纳入40例不适合手术或放疗的皮肤鳞状细胞癌患者,每日口服吉非替尼250 mg直至疾病进展或不耐受。37例可评估患者中总缓解率为16%(6例部分缓解),8周时另有35%患者疾病稳定,中位缓解持续时间31.4个月,中位无进展生存期3.8个月;预设20%目标缓解率未达到,但安全性良好。
要点
- 吉非替尼在不可治愈性CSCC中总缓解率为16%,未达预设20%目标。
- 8周时35%患者疾病稳定,中位无进展生存期3.8个月。
- 不良反应谱与其他肿瘤类型中吉非替尼既往经验一致。
核心结论
- 吉非替尼在不可治愈性皮肤鳞状细胞癌中显示出适度活性,且不良事件谱良好。
研究设计与样本
- 单臂II期研究,共40例不适合手术或放疗的皮肤鳞状细胞癌患者接受吉非替尼250 mg口服每日一次,直至疾病进展或不耐受。
- 预设目标缓解率为20%。
主要发现
- 总缓解率为16%(95%CI 0.06-0.32),37例可评估患者中6例部分缓解。
- 另有13例(35%)在8周时疾病稳定。
- 中位缓解持续时间为31.4个月(95%CI 3.91-不可评估)。
- 中位无进展生存期为3.8个月(95%CI 2.2-5.7)。
- 不良反应谱与其他肿瘤类型中吉非替尼的既往经验一致。
关键数值与推荐
- 总缓解率16%(95%CI 0.06-0.32),37例可评估患者中6例部分缓解。
- 8周时疾病稳定13例(35%)。
- 中位缓解持续时间31.4个月(95%CI 3.91-不可评估)。
- 中位无进展生存期3.8个月(95%CI 2.2-5.7)。
- 预设目标缓解率20%未达到。
临床怎么用
- 对于不适合手术或放疗的皮肤鳞状细胞癌患者,吉非替尼可作为耐受性良好的系统治疗选择之一,但缓解率有限。
- 治疗期间需按250 mg每日一次口服给药,持续至疾病进展或不耐受。
局限性
- 单中心、单臂研究设计。
- 预设目标缓解率未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC. OBJECTIVE: To determine the response rate to gefitinib in patients with CSCC not amenable to curative therapy including surgery or radiation. METHODS: This was a single-arm phase II study. A total of 40 patients were treated with gefitinib, 250 mg orally daily, until disease progression or intolerable toxicities. The prespecified target response rate of interest was 20%. RESULTS: The overall response rate was 16% (95% confidence interval, 0.06-0.32; 6 partial responses in 37 evaluable patients). An additional 13 patients (35%) had stable disease at 8 weeks. The median durations of response and progression-free survival were 31.4 months (95% confidence interval, 3.91-not applicable) and 3.8 months (95% confidence interval, 2.2-5.7), respectively. The side effect profile was consistent with the previous experience with gefitinib in other tumor types. LIMITATIONS: This was a single-institution, single-arm study. The prespecified target response rate was not met. CONCLUSION: Gefitinib demonstrated modest activity in incurable CSCC, with a favorable adverse event profile.
引用
- William WN, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017. PMID: 28964539. doi:10.1016/j.jaad.2017.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。